2seventy bio (TSVT) 8-K 2seventy bio Announces Expanded Collaboration Agreement with Novo Nordisk to Continue Development of in vivo Gene Editing Approach

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to

Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 6, 2022

2seventy bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

_____________________________________________________________

Delaware		001-40791	86-3658454
(State or Other Jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer Identification No.)
60 Binney Street,			02142
Cambridge,	MA
(Address of Principal Executive Offices)			(Zip Code)

Registrant’s Telephone Number, Including Area Code: (339) 499-9300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	TSVT	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 6, 2022, 2seventy bio, Inc. issued a press release announcing that it has entered into an option and license agreement with Novo Nordisk for the joint research and development of an in vivo gene editing treatment for hemophilia A and that it has entered into an agreement with Genevant Sciences for access to Genevant’s industry-leading LNP technology platform for use in the collaboration with Novo Nordisk. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of 2seventy bio, Inc., dated January 6, 2022.

__________________

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	2seventy bio, Inc.
Dated: January 6, 2022	By:	/s/ Nick Leschly
		Name: Nick Leschly
		Title: Chief Executive Officer